New research from Mass General Brigham challenges the idea of reclassifying the lowest grade of prostate cancer, Gleason Grade Group (GGG) 1, as ‘benign.’ Analyzing data from over 10,000 patients in Germany, the study found that 8% of GGG1 patients had more aggressive cancer than initially indicated. High PSA levels and extensive positive biopsy samples can identify these higher-risk patients. Keeping GGG1 as a cancer classification could improve treatment and reduce the risk of death. The findings are published in European Urology Oncology.
0
